GO
Loading...

Johnson & Johnson

More

  • Early Glance: Medical Devices companies Wednesday, 17 Dec 2014 | 10:16 AM ET

    Allergan rose $1.31 or. 6 percent, to $207.06. Baxter International Inc. rose$. 83 or 1.2 percent, to $71.56. Boston Scientific Corp. rose$. 05 or. 4 percent, to $13.00.

  • Early Glance: Pharmaceuticals companies Wednesday, 17 Dec 2014 | 10:16 AM ET

    Baxter International Inc. rose$. 83 or 1.2 percent, to $71.56. Bristol-Myers Squibb Co. rose$. 24 or. 4 percent, to $57.93. Eli Lilly& Co. rose$. 24 or. 3 percent, to $69.50.

  • Final Glance: Pharmaceuticals companies Tuesday, 16 Dec 2014 | 6:41 PM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $70.73. Bristol-Myers Squibb Co. fell$. 86 or 1.5 percent, to $57.69. Hospira fell $1.52 or 2.5 percent, to $58.82.

  • Final Glance: Medical Devices companies Tuesday, 16 Dec 2014 | 6:41 PM ET

    Allergan fell $3.26 or 1.6 percent, to $205.75. Baxter International Inc. fell$. 37 or. 5 percent, to $70.73. Boston Scientific Corp. rose$. 15 or 1.2 percent, to $12.95.

  • Midday Glance: Medical Devices companies Tuesday, 16 Dec 2014 | 1:20 PM ET

    Allergan fell $1.02 or. 5 percent, to $207.99. Baxter International Inc. rose$. 36 or. 5 percent, to $71.46. Boston Scientific Corp. rose$. 32 or 2.5 percent, to $13.12.

  • Midday Glance: Pharmaceuticals companies Tuesday, 16 Dec 2014 | 1:20 PM ET

    Baxter International Inc. rose$. 36 or. 5 percent, to $71.46. Bristol-Myers Squibb Co. fell$. 28 or. 5 percent, to $58.27. Hospira fell$. 57 or. 9 percent, to $59.77.

  • Early Glance: Pharmaceuticals companies Tuesday, 16 Dec 2014 | 10:20 AM ET

    Baxter International Inc. fell$. 04 or. 1 percent, to $71.06. Bristol-Myers Squibb Co. fell$. 63 or 1.1 percent, to $57.92. Hospira fell$. 37 or. 6 percent, to $59.97.

  • Early Glance: Medical Devices companies Tuesday, 16 Dec 2014 | 10:20 AM ET

    Allergan fell $1.35 or. 6 percent, to $207.66. Baxter International Inc. fell$. 04 or. 1 percent, to $71.06. Boston Scientific Corp. rose$. 19 or 1.5 percent, to $12.99.

  • Final Glance: Medical Devices companies Monday, 15 Dec 2014 | 6:08 PM ET

    Allergan rose$. 54 or. 3 percent, to $209.01. Baxter International Inc. fell$. 67 or. 9 percent, to $71.10. Boston Scientific Corp. fell$. 20 or 1.5 percent, to $12.80.

  • Final Glance: Pharmaceuticals companies Monday, 15 Dec 2014 | 6:08 PM ET

    Baxter International Inc. fell$. 67 or. 9 percent, to $71.10. Bristol-Myers Squibb Co. fell$. 20 or. 3 percent, to $58.55. Hospira rose$. 01 or percent, to $60.34.

  • Early Glance: Medical Devices companies Monday, 15 Dec 2014 | 12:00 PM ET

    Allergan rose $1.40 or. 7 percent, to $209.87. Baxter International Inc. rose$. 15 or. 2 percent, to $71.92. St. Jude Medical Inc. rose$. 15 or. 2 percent, to $66.48.

  • Early Glance: Pharmaceuticals companies Monday, 15 Dec 2014 | 12:00 PM ET

    Baxter International Inc. rose$. 15 or. 2 percent, to $71.92. Bristol-Myers Squibb Co. fell$. 15 or. 3 percent, to $58.60. Hospira rose $1.01 or 1.7 percent, to $61.34.

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • LONDON/ GENEVA, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines, as one experimental shot hit a snag in a Swiss clinical trial after some subjects reported joint pains. GAVI, which is funded by governments and the Bill& Melinda Gates Foundation, said it was ready to begin procurement as soon as the...

  • LONDON, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines and was ready to begin procurement as soon as the World Health Organization recommends one for use. Clinical trials with experimental shots are now underway as experts race to contain an epidemic that has killed more than 6,000 people in...

  • It spent $5.7 billion for the rights to some injectable wrinkle treatments of Valeant Pharmaceuticals and for L'Oreal's share of a dermatology joint venture the two operated. Nestle is also spending about $350 million on dermatology research and development this year, said Humberto Antunes, chief executive of Nestle Skin Care. The first of the new research...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • CHICAGO, Dec 9- The U.S. Department of Health and Human Services on Tuesday offered liability protections to drugmakers rushing to develop Ebola vaccines and urged other countries to follow suit. Health and Human Services Secretary Sylvia Burwell made the announcement as part of the Public Readiness and Emergency Preparedness Act in a move aimed at...

  • The sukuk from the International Finance Facility for Immunization Co, for which the World Bank acts as treasury manager, is a break from the predominantly commercial nature of most Islamic finance transactions. The deal is part of World Bank efforts to adapt sukuk for use in a variety of ethical pursuits, including advising the Dubai government on a funding...

  • Dec 4- The top U.S. patent appeals court has thrown out a $176 million award for healthcare company Covidien Plc in a dispute with a Johnson& Johnson subsidiary over surgical instruments. Judge Sharon Prost of the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., ruled on Thursday that Covidien's patent claims, which involve surgical cutting tools...